Diagnostic and prognostic value of preoperative combined GFAP, IGFBP‐2, and YKL‐40 plasma levels in patients with glioblastoma

Circulating proteins released by tumor cells have recently been investigated as potential single surrogate biomarkers for glioblastoma multiforme (GBM). The aim of the current hypothesis‐generating study was to evaluate the diagnostic and prognostic role of preoperative insulin‐like growth factor‐binding protein 2 (IGFBP‐2), chitinase‐3‐like protein 1 (YKL‐40), and glial fibrillary acidic protein (GFAP) plasma levels in patients with GBM, both as single markers and as a combined profile.

[1]  C. Bettegowda,et al.  Pre- and post-operative plasma glial fibrillary acidic protein levels in patients with newly diagnosed gliomas , 2012, Journal of Neuro-Oncology.

[2]  R. Scienza,et al.  Serum YKL-40 following resection for cerebral glioblastoma , 2012, Journal of Neuro-Oncology.

[3]  L. Deangelis,et al.  Serum YKL-40 is a marker of prognosis and disease status in high-grade gliomas. , 2011, Neuro-oncology.

[4]  L. Deangelis,et al.  Longitudinal prospective study of matrix metalloproteinase-9 as a serum marker in gliomas , 2011, Journal of Neuro-Oncology.

[5]  Wei Zhang,et al.  Plasma IGFBP-2 levels predict clinical outcomes of patients with high-grade gliomas. , 2009, Neuro-oncology.

[6]  H. Steinmetz,et al.  Serum GFAP is a diagnostic marker for glioblastoma multiforme. , 2007, Brain : a journal of neurology.

[7]  L. Rosengren,et al.  Serum levels of glial fibrillary acidic protein correlate to tumour volume of high‐grade gliomas , 2007, Acta neurologica Scandinavica.

[8]  G. Fuller,et al.  Insulin-like growth factor binding protein 2 promotes glioma development and progression , 2007, Proceedings of the National Academy of Sciences.

[9]  S. Horvath,et al.  Insulin growth factor-binding protein 2 is a candidate biomarker for PTEN status and PI3K/Akt pathway activation in glioblastoma and prostate cancer , 2007, Proceedings of the National Academy of Sciences.

[10]  L. Deangelis,et al.  YKL-40 and Matrix Metalloproteinase-9 as Potential Serum Biomarkers for Patients with High-Grade Gliomas , 2006, Clinical Cancer Research.

[11]  T. Neumann-Haefelin,et al.  Serum glial fibrillary acidic protein as a biomarker for intracerebral haemorrhage in patients with acute stroke , 2005, Journal of Neurology, Neurosurgery & Psychiatry.

[12]  W. Hop,et al.  Low-Molecular Weight Caldesmon as a Potential Serum Marker for Glioma , 2005, Clinical Cancer Research.

[13]  N. Seki,et al.  Cathepsin D is a potential serum marker for poor prognosis in glioma patients. , 2005, Cancer research.

[14]  R. Mirimanoff,et al.  MGMT gene silencing and benefit from temozolomide in glioblastoma. , 2005, The New England journal of medicine.

[15]  A. Raabe,et al.  Glial fibrillary acidic protein in serum after traumatic brain injury and multiple trauma. , 2004, The Journal of trauma.

[16]  E. Stopa,et al.  Cerebrospinal fluid (vascular endothelial growth factor) and serologic (recoverin) tumor markers for malignant glioma. , 2004, Cancer control : journal of the Moffitt Cancer Center.

[17]  Mark R Gilbert,et al.  Gene expression microarray analysis reveals YKL-40 to be a potential serum marker for malignant character in human glioma. , 2002, Cancer research.

[18]  O. Kallioniemi,et al.  Identification of differentially expressed genes in human gliomas by DNA microarray and tissue chip techniques. , 2000, Cancer research.

[19]  R. Prayson,et al.  Evaluation of epithelial and keratin markers in glioblastoma multiforme: an immunohistochemical study. , 1999, Archives of pathology & laboratory medicine.

[20]  T Brott,et al.  The ABCs of measuring intracerebral hemorrhage volumes. , 1996, Stroke.

[21]  H. Heinzl,et al.  Exploratory investigation of eight circulating plasma markers in brain tumor patients , 2012, Neurosurgical Review.

[22]  F. Ducray,et al.  IDH1 and IDH2 mutations in gliomas. , 2009, The New England journal of medicine.

[23]  Manfred Herrmann,et al.  Brain derived proteins as markers of acute stroke: their relation to pathophysiology, outcome prediction and neuroprotective drug monitoring. , 2003, Restorative neurology and neuroscience.

[24]  J Zhang,et al.  Use of microgenomic technology for analysis of alterations in DNA copy number and gene expression in malignant melanoma. , 1997, Clinical and experimental immunology.

[25]  D. Schreiber,et al.  [A simple method for the isolation of GFAP and its use for the study of brain tumors]. , 1989, Zentralblatt fur allgemeine Pathologie u. pathologische Anatomie.